Author

Lauren Stott

Brighton and Sussex Medical SchoolORCID 0009-0005-9400-6642Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:comparative / phylogenetic analysis· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

Aimilia VareliiD· 2 shared Andrea G. S. PepperiD· 2 shared Chris J. PepperiD· 2 shared Emma KennedyiD· 2 shared Fabio A. SimoesiD· 2 shared Simon A. MitchelliD· 2 shared Alexander HoffmanniD· 1 shared Amarpreet DeviiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aimilia VareliORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Death and DiseasePeer-reviewedAug 16, 2025

Systems biology-enabled targeting of NF-κB and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.

Aimilia Vareli, Haripriya Vaidehi Narayanan, Heather Clark…·Simon A. Mitchell

This study identifies resistance mechanisms to BH3-mimetics in DLBCL and shows that combining BCL2 inhibition with non-canonical NF-κB inhibition overcomes microenvironment-mediated resistance.

7 citations

humanflow cytometry

𝕏 PostBluesky

Cancer BiologyCancersPeer-reviewedJan 3, 2025

A novel in-vitro model of the bone marrow microenvironment in AML identifies CD44 and Focal Adhesion Kinase as therapeutic targets to reverse cell adhesion-mediated drug resistance

Eleni E Ladikou, K. Sharp, Fabio A. Simoes…·Andrea G. S. Pepper

This study identifies CD44 and FAK as therapeutic targets to reverse adhesion-mediated drug resistance in AML by developing an in-vitro BMME model and testing their synergistic effects.

4 citations

humanbulk RNA-seq

𝕏 PostBluesky